Media ReleasesMediVac

View All MediVac News

MediVac Limited (ASX:MDV) MediVac attracts strong interest from US investors

MediVac Attracts Strong Interest from US Investors and Featured on Boardroom Radio
Healthcare solutions company MediVac Limited [ASX: MDV] advises that it has recently completed a successful investor road show in the United States of America.
Executive Chairman Paul McPherson met with and formally presented MediVac’s credentials to more than 100 stockbrokers, fund managers, institutional investors, high net worth investors, family company managers etc in New York, Philadelphia, Orlando, West Palm Beach and Boca Raton. Mr. McPherson received positive feedback about the Company’s products and future prospects.
The road show was facilitated by Arrowhead Business and Investment Decisions, LLC, which recently issued a research report on MediVac (previously announced to ASX).
Boardroom Radio recently interviewed Thomas Renaud, managing partner at Arrowhead, on the rerating of Medivac and its prospects. The interview can be heard by accessing the link on MediVac’s Web Site under the Investor / Boardroom Radio podcasts tabs or the Boardroom Radio website.
Following almost universal recommendations from prospective US investors, the Company will also investigate the possibility of its shares being quoted on the US OTC QX. The OTC QX market provides a cost effective means for increased visibility and exposure to US institutional and retail investors, facilitating investment in MediVac. It also creates liquidity and diversifies the Company’s shareholder base, and has the potential to increase both Australian and global trading volume and value.
During his trip, Mr. McPherson visited the OTC QX headquarters and met with several parties who can provide the requisite Principal American Liaison (PAL) service and issue the American Deposit Receipts (ADRs), which are used to trade the Company’s securities in the USA.
Mr. McPherson said, “I was very impressed with the strong attendance and interest in our presentations, the depth of questions asked and the strong interest in investing in MediVac. There was widespread support for the Company to have its securities quoted on the QX. Many prominent ASX-listed companies – both large and small – have undertaken this course of action and, from the case studies I have viewed, have received very positive results in increased liquidity and market value.”
The Company will keep the market informed as to its progress on this initiative.
Download this document